2. Search Result
Search Result
Results for "

Gilteritinib

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12432
    Gilteritinib
    35+ Cited Publications

    ASP2215

    		 FLT3 TAM Receptor Cancer
    Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
    Gilteritinib
  • HY-12432R
    Gilteritinib (Standard)

    ASP2215 (Standard)

    		 Reference Standards FLT3 TAM Receptor Cancer
    Gilteritinib (Standard) is the analytical standard of Gilteritinib. This product is intended for research and analytical applications. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
    Gilteritinib (Standard)
  • HY-12432S1
    Gilteritinib-d8

    ASP2215-d8

    		 FLT3 TAM Receptor Cancer
    Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
    Gilteritinib-d8
  • HY-12432A
    Gilteritinib hemifumarate
    35+ Cited Publications

    ASP2215 hemifumarate

    		 FLT3 TAM Receptor Cancer
    Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively.
    Gilteritinib hemifumarate
  • HY-12432AR
    Gilteritinib hemifumarate (Standard)

    		FLT3 TAM Receptor Cancer
    Gilteritinib hemifumarate (Standard) is the analytical standard of Gilteritinib hemifumarate. This product is intended for research and analytical applications. Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively.
    Gilteritinib hemifumarate (Standard)
  • HY-169374
    Naproxen Gilteritinib

    		Ligands for Target Protein for PROTAC Cancer
    Naproxen Gilteritinib is the active reference substance of Gilteritinib (HY-12432). Gilteritinib is the target protein ligand of PROTAC degrader LWY713 (HY-157213) .
    Naproxen Gilteritinib
  • HY-157213
    LWY713

    		Apoptosis PROTACs FLT3 Cancer
    LWY713 is a PROTAC-class FLT3 degrader (DC50=0.64 nM), which selectively induces FLT3 degradation via cereblon and proteasome-dependent pathways. LWY713 inhibits cell proliferation and induces G0/G1 phase arrest and apoptosis in MV4-11 cells. LWY713 shows effective in vivo antitumor activity in MV4-11 xenograft models . LWY713 consists of a target protein ligand (red part) Gilteritinib (HY-12432), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC linker (black part) Glycolic acid (HY-W015967). E3 ubiquitin ligase and linker can form Lenalidomide-Glycolic acid (HY-169373); the active control for the target protein ligand is Naproxen Gilteritinib (HY-169374).
    LWY713
  • HY-159953
    IRAK1/4/pan-FLT3 Kinase-IN-1

    		IRAK FLT3 Cancer
    IRAK1/4/pan-FLT3 Kinase-IN-1 (Compound 31) is a potent inhibitor of IRAK1, IRAK4, and FLT3 kinases, with an IC50 of 5 nM for IRAK1, 0.6 nM for IRAK4, and less than 0.5 nM for FLT3. IRAK1/4/pan-FLT3 Kinase-IN-1 has good pharmacokinetic properties and shows promising potential for research in acute myeloid leukemia, with a survival prolongation effect comparable to that of Gilteritinib (HY-12432) .
    IRAK1/4/pan-FLT3 Kinase-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: